Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

Abstract

Pancreatic cancer is a relatively common tumor of the digestive system， with difficulties in early-stage diagnosis and an extremely high degree of malignancy. Molecular diagnostic technology based on tumor biomarkers， combined with the existing gold standard in clinical practice， is of great clinical significance to achieve early accurate identification， timely treatment and intervention， and reduction in mortality. Previous studies have shown that miRNAs show high specificity in terms of types and expression levels in different pathological stages of pancreatic cancer and can thus be used in monitoring the development and progression of pancreatic cancer. Since a single miRNA has a limited diagnostic potential， the combination of different miRNAs may effectively improve the diagnostic efficiency of early-stage pancreas carcinogenesis. Based on related research advances in recent years， this consensus document aims to fill the gap in molecular diagnostic technology in the guidelines for the clinical diagnosis and treatment of pancreatic cancer and provide expert guidance and recommendations.
- Pancreatic Neoplasms,
- Early Detection of Cancer,
- Biomarkers， Tumor,
- MicroRNAs,
- Expert Consensus

FullText(HTML)

References(20)

References

[1]	ZHENG RS, ZHANG SW, ZENG HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2( 1): 1- 9. DOI: 10.1016/j.jncc.2022.02.002.
[2]	KANDA M, MATTHAEI H, WU J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia[J]. Gastroenterology, 2012, 142( 4): 730- 733. e 9. DOI: 10.1053/j.gastro.2011.12.042.
[3]	MARIN AM, BATISTA M, de AZEVEDO ALK, et al. Screening of exosome-derived proteins and their potential as biomarkers in diagnostic and prognostic for pancreatic cancer[J]. Int J Mol Sci, 2023, 24( 16): 12604. DOI: 10.3390/ijms241612604.
[4]	HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144( 5): 646- 674. DOI: 10.1016/j.cell.2011.02.013.
[5]	HUANG J, GAO G, GE Y, LIU JZ, et al. Development of a serum-based microRNA signature for early detection of pancreatic cancer: a multicenter cohort study[J]. Dig Dis Sci, 2024.[Forthcoming]
[6]	LI H, CHIANG CL, KWAK KJ, et al. Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis[J]. Adv Sci(Weinh), 2024. DOI: 10.1002/advs.202306373.[ Online ahead of Print]
[7]	KAMAL MA, SIDDIQUI I, BELGIOVINE C, et al. Oncogenic KRAS-induced protein signature in the tumor secretome identifies laminin-C2 and pentraxin-3 as useful biomarkers for the early diagnosis of pancreatic cancer[J]. Cancers(Basel), 2022, 14( 11): 2653. DOI: 10.3390/cancers14112653.
[8]	CAVE DD, BUONAIUTO S, SAINZ B Jr, et al. LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer[J]. J Exp Clin Cancer Res, 2022, 41( 1): 315. DOI: 10.1186/s13046-022-02516-w.
[9]	CHEN XB, LIAO XM, ZHENG BL, et al. Differential plasma proteins identified via iTRAQ-based analysis serve as diagnostic markers of pancreatic ductal adenocarcinoma[J]. Dis Markers, 2023, 2023: 5145152. DOI: 10.1155/2023/5145152.
[10]	LUO XL, LIU JJ, WANG HZ, et al. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis[J]. Pharmacol Res, 2020, 156: 104805. DOI: 10.1016/j.phrs.2020.104805.
[11]	ZHAO R, REN S, LI CY, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study[J]. Cancer Med, 2023, 12( 4): 5158- 5171. DOI: 10.1002/cam4.5296.
[12]	CAO YY, ZHAO R, GUO K, et al. Potential metabolite biomarkers for early detection of stage-I pancreatic ductal adenocarcinoma[J]. Front Oncol, 2022, 11: 744667. DOI: 10.3389/fonc.2021.744667.
[13]	SAHNI S, PANDYA AR, HADDEN WJ, et al. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma[J]. Int J Cancer, 2021, 148( 6): 1508- 1518. DOI: 10.1002/ijc.33368.
[14]	SKUBISZ K, DĄBKOWSKI K, SAMBOROWSKA E, et al. Serum metabolite biomarkers for pancreatic tumors: Neuroendocrine and pancreatic ductal adenocarcinomas-a preliminary study[J]. Cancers(Basel), 2023, 15( 12): 3242. DOI: 10.3390/cancers15123242.
[15]	EISSA MAL, LERNER L, ABDELFATAH E, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood[J]. Clin Epigenetics, 2019, 11( 1): 59. DOI: 10.1186/s13148-019-0650-0.
[16]	LI SY, WANG L, ZHAO Q, et al. Genome-wide analysis of cell-free DNA methylation profiling for the early diagnosis of pancreatic cancer[J]. Front Genet, 2020, 11: 596078. DOI: 10.3389/fgene.2020.596078.
[17]	SCHOTT S, YANG RX, STÖCKER S, et al. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: A case control study[J]. Oncotarget, 2017, 8( 40): 67614- 67625. DOI: 10.18632/oncotarget.18757.
[18]	WU YN, SEUFERT I, AL-SHAHERI FN, et al. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma[J]. Gut, 2023, 72( 12): 2344- 2353. DOI: 10.1136/gutjnl-2023-330155.
[19]	MAKLER A, ASGHAR W. Exosomal miRNA biomarker panel for pancreatic ductal adenocarcinoma detection in patient plasma: A pilot study[J]. Int J Mol Sci, 2023, 24( 6): 5081. DOI: 10.3390/ijms24065081.
[20]	XIAO D, DONG ZJ, ZHEN LQ, et al. Combined exosomal GPC1, CD82, and serum CA19-9 as multiplex targets: A specific, sensitive, and reproducible detection panel for the diagnosis of pancreatic cancer[J]. Mol Cancer Res, 2020, 18( 2): 300- 310. DOI: 10.1158/1541-7786.MCR-19-0588.

Relative Articles

[1]	Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
[2]	Committee of Minimally Invasive Therapy in Oncology， Chinese Anti-Cancer Association, Committee of Ablation Therapy in Oncology， Chinese Anti-Cancer Association. Chinese expert consensus on Co-Ablation System for the treatment of primary liver cancer （2023 edition）[J]. Journal of Clinical Hepatology, 2023, 39(12): 2793-2797.
[3]	Yao ZHANG, Kai ZHANG, Pengdong KANG, Chao MA. Research advances in microRNA-200c in pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(4): 961-964. doi: 10.3969/j.issn.1001-5256.2022.04.045
[4]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[5]	Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
[6]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[7]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[8]	Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
[9]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[10]	Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
[11]	Cheng YaFei, Wang Bin, Wang ShiMing. Role of microRNAs in gallbladder carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1900-1904. doi: 10.3969/j.issn.1001-5256.2020.08.049
[12]	Wang ZhiXin, Gou Ping, Yu WenHao, Ren Li, Yang DanCaiRang, Wang HaiJiu, Fan HaiNing. Measurement and bioinformatics analysis of exosomes microRNAs in bile of hepatic alveolar echinococcosis patients with biliary tract invasion[J]. Journal of Clinical Hepatology, 2020, 36(9): 2045-2049. doi: 10.3969/j.issn.1001-5256.2020.09.027
[13]	Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
[14]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[15]	Zhang YuRui. Correlation between microRNA-520a and clinicopathological features of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(4): 689-693. doi: 10.3969/j.issn.1001-5256.2017.04.018
[16]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[17]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[20]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008

Supplements(0)

Cited By

Cited by
Periodical cited type(1)
1. 孙宁，谈震，李潇箫，黑发贤，郭卫东，马凯. 胰腺癌新辅助治疗序贯外科手术切除一例. 肝胆胰外科杂志. 2025(01): 42-46 .
Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (1028) PDF downloads(449)

Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

DOI: 10.12449/JCH240306

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

DOI: 10.12449/JCH240306

Abstract

References

Relative Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content